About JPMA
The Japan Pharmaceutical Manufacturers Association (JPMA) is a voluntary organization comprising 69 research and development-based pharmaceutical companies (as of September 1, 2025). Since its foundation in 1968, with the mission of realizing patient-oriented healthcare, JPMA has contributed to the development of global healthcare through the research and development of innovative pharmaceutical products.
In recent years, the diversification of medical needs and the rapid advancement of life science technologies have made drug discovery complex and sophisticated. To address these changes, JPMA is promoting the establishment and strengthening of a drug discovery ecosystem through industry-academia-government collaboration. In addition, JPMA is focusing on resolving common issues within the pharmaceutical industry and fostering a deeper public understanding of pharmaceuticals. These activities are primarily developed through committees and specialized organizations composed of members from various member companies, leading to policy recommendations and enhanced dialogue with society.
Internationally, JPMA operates as one of the major pharmaceutical associations alongside the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). JPMA participates as a founding industry member in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) to develop international regulations, and contributes to improving access to medicines in Asia by leading the Asia Partnership Conference of Pharmaceutical Associations (APAC). Furthermore, as a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), JPMA addresses various global health issues, including improving access to medicines, protecting intellectual property, combating infectious diseases, and promoting the Sustainable Development Goals (SDGs).
Moving forward, JPMA will further strengthen its collaboration with domestic and international organizations and various stakeholders to enhance the transparency and trustworthiness of the entire Japanese pharmaceutical industry and ensure its continued sound development. Through co-creation with the public, including patients, JPMA will drive innovation and contribute to improving the health and Quality of Life (QOL) of people worldwide.